The British private equity firm Cinven has announced the acquisition of Amdipharm, an international speciality pharmaceutical company, for £367 million.
Amdipharm will initially operate as an independent company, and then over time merge with the pharmaceutical company pharmaceuticals Mercury, which took over Cinven in September 2012.
The London-based private equity firm pushes ahead with this transaction, as part of the implementation of its consolidation strategy within the speciality pharmaceutical industry, making this the fourth investment from the Investment Fund V and the fifth investment in 2012 in total.
Amdipharm pharmaceutical products‘ home market is in the UK, but are available in over 80 countries globally.
[ilink url=“http://www.aerztezeitung.de/praxis_wirtschaft/unternehmen/article/824107/uebernahme-investor-cinven-schluckt-amdipharm.html“] Link zur Quelle (Ärzte Zeitung)[/ilink]